See the DrugPatentWatch profile for lurbinectedin

Yes, serious side effects are possible with the use of lurbinectedin over time. Lurbinectedin is a novel anticancer drug that has been approved by the European Medicines Agency (EMA) for the treatment of adult patients with certain types of relapsed or refractory solid tumors, such as small cell lung cancer (SCLC) [1]. However, like many other anticancer drugs, lurbinectedin can cause various side effects, some of which can be serious or life-threatening, especially with long-term use.

According to the summary of product characteristics (SmPC) of lurbinectedin, the most common side effects (occurring in >30% of patients) include neutropenia, nausea, fatigue, and increased liver enzymes [2]. Neutropenia, in particular, can increase the risk of infection and may require dose modifications or interruptions. Other serious side effects (occurring in <10% of patients) include thrombocytopenia, anemia, febrile neutropenia, pneumonia, and sepsis [2].

Moreover, lurbinectedin can cause long-term or irreversible damage to various organs and tissues, such as the liver, kidneys, and nervous system [2]. For example, the SmPC states that lurbinectedin may cause hepatotoxicity, nephrotoxicity, and peripheral neuropathy, which may require permanent discontinuation of the drug [2].

Therefore, it is crucial to monitor patients closely for signs and symptoms of side effects during and after lurbinectedin treatment, and to adjust the dose or discontinue the drug as necessary [2]. Healthcare professionals should also inform patients of the risks and benefits of lurbinectedin therapy and provide appropriate counseling and support [2].

In summary, while lurbinectedin can be an effective treatment option for certain types of relapsed or refractory solid tumors, it can also cause serious side effects, especially with long-term use. Healthcare professionals should carefully evaluate the risks and benefits of lurbinectedin therapy and monitor patients closely for side effects during and after treatment.

Sources:

1. DrugPatentWatch.com. Lurbinectedin. Available at: <https://www.drugpatentwatch.com/drugs/lurbinectedin>.
2. European Medicines Agency. Zepzelca (lurbinectedin). Summary of product characteristics. Available at: <https://www.ema.europa.eu/en/documents/product-information/zepzelca-epar-product-information_en.pdf>.